Scarica l'app Stockscreener
0.5767
5.51%
0.0301
Pre-mercato:
.60
0.0233
+4.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.5466
Aprire:
$0.5527
Volume 24 ore:
2.44M
Relative Volume:
0.54
Capitalizzazione di mercato:
$168.40M
Reddito:
-
Utile/perdita netta:
$-63.08M
Rapporto P/E:
-2.1359
EPS:
-0.27
Flusso di cassa netto:
$-72.53M
1 W Prestazione:
+0.56%
1M Prestazione:
-12.62%
6M Prestazione:
-51.94%
1 anno Prestazione:
-41.39%
Intervallo 1D:
$0.5527
$0.5845
Intervallo di 1 settimana:
$0.517
$0.6876
Portata 52W:
$0.517
$2.105
Ocugen Inc Stock (OCGN) Company Profile
Nome
Ocugen Inc
Settore
Industria
Telefono
484-328-4701
Indirizzo
11 GREAT VALLEY PARKWAY, MALVERN, PA
Confronta OCGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.5767 | 168.40M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-15 | Iniziato | Maxim Group | Buy |
| 2023-03-01 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Iniziato | Mizuho | Buy |
| 2022-06-15 | Ripresa | ROTH Capital | Buy |
| 2022-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Iniziato | Noble Capital Markets | Outperform |
| 2021-06-11 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
Mostra tutto
Ocugen Inc Borsa (OCGN) Ultime notizie
Ocugen Inc. Navigates Uncertainty Amid Potential Shifts in U.S. Fiscal and Tax Policies - MSN
SBI Securities Co. Ltd. Makes New $40,000 Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Acquired by Rhumbline Advisers - Defense World
Equities Analysts Offer Predictions for Ocugen Q1 Earnings - Defense World
FY2029 Earnings Estimate for Ocugen Issued By HC Wainwright - Defense World
Ocugen’s (OCGN) “Buy” Rating Reiterated at HC Wainwright - Defense World
Ocugen Secures ATMP Classification for Gene Therapies Targeting Vision Loss - MSN
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN
Ocugen’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Ocugen Reports 2024 Financial Results and Advances Gene Therapy Programs - MSN
Attention Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating -March 06, 2025 at 08:15 am EST - Marketscreener.com
Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call Transcript - Insider Monkey
Ocugen’s Strategic BLA Submissions and Financial Position Support Buy Rating - TipRanks
Beyond The Numbers: 5 Analysts Discuss Ocugen Stock - Benzinga
Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen: Q4 Earnings Snapshot - Midland Daily News
Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Ocugen Inc Earnings Call: Strategic Gains Amid Financial Challenges - TipRanks
Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025 - CGTLive™
Ocugen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Stock Quote & Chart - Ocugen
Ocugen (OCGN) Q4 2024 Earnings Call Transcript - Yahoo
Ocugen’s Geographic Atrophy and Stargardt Gene Therapies Garner Positive ATMP Opinions from EMA - CGTLive™
Earnings call transcript: Ocugen Q4 2024 beats earnings forecast By Investing.com - Investing.com UK
Ocugen to Announce Q4 and Full-Year 2024 Results with Live Webcast on March 5, 2025 - MSN
Ocugen, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Ocugen Q4 2024 beats earnings forecast - Investing.com
Ocugen Inc (OCGN) Q4 Earnings: Revenue Surpasses Estimates at $0 - GuruFocus.com
OCGN Earnings: Ocugen Stock Jumps on Q4 Results & Development Updates - Markets Insider
Ocugen reports Q4 EPS (5c), consensus (5c) - TipRanks
OCUGEN Earnings Results: $OCGN Reports Quarterly Earnings - Nasdaq
Ocugen: Q4 Earnings Snapshot -March 05, 2025 at 07:23 am EST - Marketscreener.com
Ocugen, Inc. Reports Progress on Clinical Trials and FDA Alignment for OCU410ST in Stargardt Disease, Highlights Positive Long-Term Data for OCU400 - Nasdaq
Ocugen stock hits 52-week low at $0.6 amid market challenges - Investing.com
Ocugen Announces Positive Opinion of EMA’s Committee for - GlobeNewswire
Ocugen Announces Positive Opinion Of EMA'S Committee For Advanced Therapies For ATMP Classification - Marketscreener.com
Ocugen announces EC provided position opinion from EMA’s CAT for OCU410 - TipRanks
Ocugen gains EU nod for gene therapy classifications - Investing.com India
Ocugen's Eye Disease Gene Therapies Show 44-52% Slower Lesion Growth After EMA Regulatory Win - StockTitan
Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN) - Financial Post
Grabar Law Office is Investigating Claims on Behalf of - GlobeNewswire
Ocugen Inc Azioni (OCGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):